{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:33:44Z","timestamp":1740126824744,"version":"3.37.3"},"reference-count":111,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Eine erfolgreiche Therapie psychischer St\u00f6rungen ist angesichts des\n                    h\u00e4ufig vorhandenen Leidensdrucks der Betroffenen sehr wichtig. Da\n                    anerkannte pharmazeutische und psychotherapeutische Ans\u00e4tze leider nicht\n                    f\u00fcr alle Patient:innen zur erw\u00fcnschten Besserung ihres Leidens\n                    f\u00fchren, findet intensive Forschung zu erg\u00e4nzenden oder\n                    alternativen Behandlungsmethoden statt. Besonders vielversprechend zeigte sich\n                    zuletzt die Psilocybin-gest\u00fctzte Psychotherapie, die in den USA deshalb\n                    f\u00fcr klinische Studien mit gr\u00f6\u00dferen Stichproben als\n                    bisher zugelassen wurde. Psilocybin geh\u00f6rt zu den Psychedelika und\n                    beeinflusst in seiner Wirkung das psychische Erleben. Bei der gest\u00fctzten\n                    Therapie wird Psilocybin in kontrollierten Dosen unter medizinischer Aufsicht\n                    verabreicht. In den bisher durchgef\u00fchrten Studien konnten bereits nach\n                    einer, bis wenigen Einnahmen l\u00e4ngerfristige positive Effekte in Hinblick\n                    auf die jeweiligen St\u00f6rungsbilder gezeigt werden. Um ein besseres\n                    Verst\u00e4ndnis der potenziellen therapeutischen Mechanismen zu\n                    erm\u00f6glichen, sollen in diesem Artikel zun\u00e4chst Erkenntnisse zur\n                    Wirkweise von Psilocybin auf neurobiologischer und psychologischer Ebene\n                    vorgestellt werden. Anschlie\u00dfend soll die Analyse der bisher\n                    durchgef\u00fchrten klinischen Studien mit einer Anwendung von Psilocybin bei\n                    Patient:innen helfen, das Potential der Psilocybin-gest\u00fctzten\n                    Psychotherapie f\u00fcr verschiedene St\u00f6rungsbilder besser\n                    einsch\u00e4tzen zu k\u00f6nnen.<\/jats:p>","DOI":"10.1055\/a-2046-5202","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T22:37:27Z","timestamp":1684535847000},"page":"230-245","source":"Crossref","is-referenced-by-count":0,"title":["Psilocybin-gest\u00fctzte Therapie von Depression, Angst und\n                    Suchtst\u00f6rungen: Neurobiologische Grundlagen und klinische\n                    Anwendung"],"prefix":"10.1055","volume":"92","author":[{"given":"Anna","family":"Lasch","sequence":"additional","affiliation":[{"name":"Biopsychologie, Technische Universit\u00e4t Dresden, Dresden,\n                    Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Schweikert","sequence":"additional","affiliation":[{"name":"Psychotherapie und Systemneurowissenschaften,\n                    Justus-Liebig-Universit\u00e4t Gie\u00dfen, Gie\u00dfen,\n                    Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Dora","sequence":"additional","affiliation":[{"name":"Biopsychologie, Technische Universit\u00e4t Dresden, Dresden,\n                    Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Kolb","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus Dresden, Division\n                    Psychological and Social Medicine and Developmental Neuroscience, Dresden,\n                    Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2125-8612","authenticated-orcid":false,"given":"Hanne Lilian","family":"Schurig","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus Dresden, Division\n                    Psychological and Social Medicine and Developmental Neuroscience, Dresden,\n                    Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Walther","sequence":"additional","affiliation":[{"name":"Klinische Psychologie und Psychotherapie, Universit\u00e4t\n                    Z\u00fcrich Psychologisches Institut, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders:\n                    findings from the Global Burden of Disease Study 2010","volume":"382","author":"H A Whiteford","year":"2013","journal-title":"The Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an\n                    open-label feasibility study","volume":"3","author":"R L Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuroimage.2017.07.020","article-title":"Two dose investigation of the 5-HT-agonist psilocybin on relative and global\n                    cerebral blood flow","volume":"159","author":"C R Lewis","year":"2017","journal-title":"NeuroImage"},{"volume-title":"Handbook of Medical Hallucinogens","year":"2021","author":"C S Grob","key":"ref4"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1017\/CBO9780511980053.004","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood\n                    disorders","volume":"11","author":"F X Vollenweider","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0269881114568040","article-title":"Peak experiences and the afterglow phenomenon: When and how do therapeutic\n                    effects of hallucinogens depend on psychedelic experiences","volume":"29","author":"T Maji\u0107","year":"2015","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"T Passie","year":"2002","journal-title":"Addict Biol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","article-title":"Psilocybin--summary of knowledge and new perspectives","volume":"24","author":"F Tyl\u0161","year":"2014","journal-title":"Eur Neuropsychopharmacol J Eur Coll\n                    Neuropsychopharmacol"},{"key":"ref12","first-page":"270","article-title":"Some biochemical studies on psilocybin and psilogin","volume":"4","author":"A. Horita","year":"1963","journal-title":"J Neuropsychiatry"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5114\/nan.2018.81249","article-title":"Changes in default-mode network activity and functional connectivity as an\n                    indicator of psychedelic-assisted psychotherapy effectiveness","volume":"13","author":"A Ruban","year":"2018","journal-title":"Neuropsychiatr Neuropsychol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/1520-6394(2000)12:1+<2:AID-DA2>3.0.CO;2-4","article-title":"Role of serotonergic and noradrenergic systems in the pathophysiology of\n                    depression and anxiety disorders","volume":"12","author":"K J Ressler","year":"2000","journal-title":"Depress Anxiety"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jchemneu.2003.10.002","article-title":"The human raphe nuclei and the serotonergic system","volume":"26","author":"J-P. Hornung","year":"2003","journal-title":"J Chem Neuroanat"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","article-title":"Serotonin research: Contributions to understanding psychoses","volume":"29","author":"M A Geyer","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/1099-1077(200008)15:6<397:AID-HUP212>3.0.CO;2-L","article-title":"A review of the role of serotonin receptors in psychiatric disorders","volume":"15","author":"M Naughton","year":"2000","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.biopsych.2019.12.027","article-title":"Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity","volume":"88","author":"K H Preller","year":"2020","journal-title":"Biol Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","article-title":"Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced\n                    Positive Mood in Healthy Volunteers","volume":"78","author":"R Kraehenmann","year":"2015","journal-title":"Biol Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.biopsych.2012.04.005","article-title":"Psilocybin biases facial recognition, goal-directed behavior, and mood state\n                    toward positive relative to negative emotions through different serotonergic\n                    subreceptors","volume":"72","author":"M Kometer","year":"2012","journal-title":"Biol Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.nicl.2015.08.009","article-title":"The mixed serotonin receptor agonist psilocybin reduces threat-induced\n                    modulation of amygdala connectivity","volume":"11","author":"R Kraehenmann","year":"2016","journal-title":"NeuroImage Clin"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2\n                    agonist action","volume":"9","author":"F X Vollenweider","year":"1998","journal-title":"Neuroreport Int J Rapid Commun Res Neurosci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/npp.2011.228","article-title":"Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are\n                    Attenuated by Ketanserin in Healthy Human Volunteers","volume":"37","author":"B B Quednow","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/ijms22020835","article-title":"A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A\n                    Receptor Density in the Pig Brain","volume":"22","author":"N R Raval","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0306-4522(87)90327-7","article-title":"Serotonin receptors in the human brain--IV. Autoradiographic mapping of\n                    serotonin-2 receptors","volume":"21","author":"A Pazos","year":"1987","journal-title":"Neuroscience"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1192\/bjp.bp.111.103309","article-title":"Implications for psychedelic-assisted psychotherapy: Functional magnetic\n                    resonance imaging study with psilocybin","volume":"200","author":"R L Carhart-Harris","year":"2012","journal-title":"Br J Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnhum.2014.00020","article-title":"The entropic brain: A theory of conscious states informed by neuroimaging\n                    research with psychedelic drugs","volume":"8","author":"R L Carhart-Harris","year":"2014","journal-title":"Front Hum Neurosci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: An integrative review of epidemiology, therapeutics,\n                    mystical experience, and brain network function","volume":"197","author":"M W Johnson","year":"2019"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","article-title":"5-HT modulation of dopamine release in basal ganglia in psilocybin-induced\n                    psychosis in Man \u2013 A PET study with [11C]raclopride","volume":"20","author":"F X Vollenweider","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","article-title":"Psychedelic Drugs in Biomedicine","volume":"38","author":"E J Kyzar","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.euroneuro.2020.02.001","article-title":"A single psilocybin dose is associated with long-term increased mindfulness,\n                    preceded by a proportional change in neocortical 5-HT2A receptor binding","volume":"33","author":"M K Madsen","year":"2020","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biopsych.2010.10.002","article-title":"The 5-HT2A\/1A agonist psilocybin disrupts modal object completion\n                    associated with visual hallucinations","volume":"69","author":"M Kometer","year":"2011","journal-title":"Biol Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and\n                    anxiety in patients with life-threatening cancer: A randomized double-blind\n                    trial","volume":"30","author":"R R Griffiths","year":"2016","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage\n                    cancer","volume":"68","author":"C S Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety\n                    and depression in patients with life-threatening cancer: A randomized controlled\n                    trial","volume":"30","author":"S Ross","year":"2016","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of\n                    personal meaning and spiritual significance 14 months later","volume":"22","author":"R R Griffiths","year":"2008","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neuropharm.2017.12.041","article-title":"Increased amygdala responses to emotional faces after psilocybin for\n                    treatment-resistant depression","volume":"142","author":"L Roseman","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and\n                    sustained personal meaning and spiritual significance","volume":"187","author":"R R Griffiths","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting\n                    dose-related effects","volume":"218","author":"R R Griffiths","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"volume-title":"Mysticism and Philosophy. 3rd ed. Edition","year":"1960","author":"WT. Stace","key":"ref41"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/7854_2017_474","article-title":"Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural\n                    Correlates","volume":"36","author":"F S Barrett","year":"2018","journal-title":"Curr Top Behav Neurosci"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised Mystical Experience Questionnaire in experimental\n                    sessions with psilocybin","volume":"29","author":"F S Barrett","year":"2015","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/jclp.20000","article-title":"The phenomenon of quantum change","volume":"60","author":"WR. Miller","year":"2004","journal-title":"J Clin Psychol"},{"volume-title":"Quantum change: When epiphanies and sudden insights transform ordinary\n                    lives","year":"2001","author":"W R Miller","key":"ref45"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy\n                    humans: a pooled analysis of experimental studies","volume":"25","author":"E Studerus","year":"2011","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/09540261.2018.1474185","article-title":"Awe: a putative mechanism underlying the effects of classic psychedelic-assisted\n                    psychotherapy","volume":"30","author":"PS. Hendricks","year":"2018","journal-title":"Int Rev Psychiatry"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/acps.12904","article-title":"Effects of psilocybin therapy on personality structure","volume":"138","author":"D Erritzoe","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111420188","article-title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases\n                    in the personality domain of openness","author":"K A MacLean","year":"2011","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000346143","article-title":"Increased Serotonin Receptor 1A Binding in Major Depressive Disorder after\n                    Psychotherapy, but Not after SSRI Pharmacotherapy, Is Related to Improved Social\n                    Functioning Capacity","volume":"82","author":"H Karlsson","year":"2013","journal-title":"Psychother Psychosom"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fpsyt.2013.00118","article-title":"Epigenetic Biomarkers as Predictors and Correlates of Symptom Improvement\n                    Following Psychotherapy in Combat Veterans with PTSD","volume":"4","author":"R Yehuda","year":"2013","journal-title":"Front Psychiatry"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.1038\/tp.2016.41","article-title":"MAOA gene hypomethylation in panic disorder-reversibility of an epigenetic risk\n                    pattern by psychotherapy","volume":"6","author":"C Ziegler","year":"2016","journal-title":"Transl Psychiatry"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","article-title":"REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of\n                    Psychedelics","volume":"71","author":"R L Carhart-Harris","year":"2019","journal-title":"Pharmacol Rev"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression:\n                    six-month follow-up","volume":"235","author":"R L Carhart-Harris","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nrn2787","article-title":"The free-energy principle: a unified brain theory","volume":"11","author":"K. Friston","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1098\/rstb.2008.0300","article-title":"Predictive coding under the free-energy principle","volume":"364","author":"K Friston","year":"2009","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.concog.2019.01.006","article-title":"Biased belief in the Bayesian brain: A deeper look at the evidence","volume":"68","author":"B M Tappin","year":"2019","journal-title":"Conscious Cogn"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fpsyt.2020.00005","article-title":"Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy\n                    Promotes Acceptance","volume":"11","author":"M Wolff","year":"2020","journal-title":"Front Psychiatry"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/09540261.2018.1474088","article-title":"Psychedelics and the new behaviourism: considering the integration of third-wave\n                    behaviour therapies with psychedelic-assisted therapy","volume":"30","author":"Z Walsh","year":"2018","journal-title":"Int Rev Psychiatry"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy\n                    and plasma psilocin levels","volume":"44","author":"M K Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fnhum.2016.00269","article-title":"Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory\n                    (EDI","volume":"10","author":"M M Nour","year":"2016","journal-title":"Front Hum Neurosci"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.neubiorev.2018.02.004","article-title":"Serotonergic psychedelics and personality: A systematic review of contemporary\n                    research","volume":"87","author":"J C Bouso","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ebiom.2016.08.049","article-title":"Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional\n                    Responses Within the Brain","volume":"11","author":"D A Martin","year":"2016","journal-title":"EBioMedicine"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1098\/rstb.2005.1661","article-title":"What is the function of the claustrum?","volume":"360","author":"F C Crick","year":"2005","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tins.2015.05.006","article-title":"Attention: The claustrum","author":"Y Goll","year":"2015","journal-title":"Trends Neurosci"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1073\/pnas.1524187113","article-title":"Effects of serotonin 2A\/1A receptor stimulation on social exclusion\n                    processing","volume":"113","author":"K H Preller","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1073\/pnas.1121358109","article-title":"Hallucinogen actions on human brain revealed","volume":"109","author":"H Lee","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1440.011","article-title":"The brain\u2019s default network: anatomy, function, and relevance to\n                    disease","volume":"1124","author":"R L Buckner","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.neuron.2010.02.005","article-title":"Functional-Anatomic Fractionation of the Brain\u2019s Default Network","volume":"65","author":"J R Andrews-Hanna","year":"2010","journal-title":"Neuron"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/nyas.12360","article-title":"The default network and self-generated thought: component processes, dynamic\n                    control, and clinical relevance","volume":"1316","author":"J R Andrews-Hanna","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-clinpsy-032511-143049","article-title":"Default mode network activity and connectivity in psychopathology","volume":"8","author":"S Whitfield-Gabrieli","year":"2012","journal-title":"Annu Rev Clin Psychol"},{"key":"ref72","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-25527-4","volume-title":"Hrsg. Kognitive Neurowissenschaften. 3. Aufl","author":"H-O Karnath","year":"2012"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.biopsych.2013.10.001","article-title":"Resting state functional connectivity and depression: in search of a bottom\n                    line","volume":"74","author":"E Leibenluft","year":"2013","journal-title":"Biol Psychiatry"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.neuroimage.2004.01.015","article-title":"Limbic-frontal circuitry in major depression: a path modeling metanalysis","volume":"22","author":"D A Seminowicz","year":"2004","journal-title":"NeuroImage"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"117456","DOI":"10.1016\/j.neuroimage.2020.117456","article-title":"Psilocybin exerts distinct effects on resting state networks associated with\n                    serotonin and dopamine in mice","volume":"225","author":"J Grandjean","year":"2021","journal-title":"NeuroImage"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain\n                    mechanisms","volume":"7","author":"R L Carhart-Harris","year":"2017","journal-title":"Sci Rep"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1511480","author":"N D Volkow","year":"2016","journal-title":"Neurobiologic Advances from the Brain Disease Model of\n                    Addiction"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.neuroimage.2010.04.251","article-title":"Nicotine replacement in abstinent smokers improves cognitive withdrawal symptoms\n                    with modulation of resting brain network dynamics","volume":"52","author":"D M Cole","year":"2010","journal-title":"NeuroImage"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"20140873","DOI":"10.1098\/rsif.2014.0873","article-title":"Homological scaffolds of brain functional networks","volume":"11","author":"G Petri","year":"2014","journal-title":"J R Soc Interface"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1002\/hbm.22562","article-title":"Enhanced repertoire of brain dynamical states during the psychedelic\n                    experience","volume":"35","author":"E Tagliazucchi","year":"2014","journal-title":"Hum Brain Mapp"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1007\/s00213-015-4026-7","article-title":"Psilocybin-induced spiritual experiences and insightfulness are associated with\n                    synchronization of neuronal oscillations","volume":"232","author":"M Kometer","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"15171","DOI":"10.1523\/JNEUROSCI.2063-13.2013","article-title":"Broadband Cortical Desynchronization Underlies the Human Psychedelic State","volume":"33","author":"S D Muthukumaraswamy","year":"2013","journal-title":"J Neurosci"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"10544","DOI":"10.1523\/JNEUROSCI.3007-12.2013","article-title":"Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on\n                    Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations","volume":"33","author":"M Kometer","year":"2013","journal-title":"J Neurosci"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neuron.2005.09.025","article-title":"Contributions of the amygdala to emotion processing: from animal models to human\n                    behavior","volume":"48","author":"E A Phelps","year":"2005","journal-title":"Neuron"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/j.1601-183X.2006.00297.x","article-title":"Serotonergic genes modulate amygdala activity in major depression","volume":"6","author":"U Dannlowski","year":"2007","journal-title":"Genes Brain Behav"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0269881119895520","article-title":"Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal\n                    functional connectivity during emotional processing after psilocybin for\n                    treatment-resistant depression","volume":"34","author":"L J Mertens","year":"2020","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with\n                    obsessive-compulsive disorder","author":"F A Moreno","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.physbeh.2017.03.040","article-title":"Long-term Follow-up of Psilocybin-facilitated Smoking Cessation","volume":"43","author":"M W Johnson","year":"2017","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco\n                    addiction","author":"M W Johnson","year":"2014","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept\n                    study","volume":"29","author":"M P Bogenschutz","year":"2015","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A\n                    Randomized Clinical Trial","author":"A K Davis","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"em296","DOI":"10.29333\/ejgm\/10862","article-title":"Effectiveness of Psilocybin on Depression: A Qualitative Study","volume":"18","author":"R A Al-Naggar","year":"2021","journal-title":"Electron J Gen Med"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1177\/00221678211022949","article-title":"Participant Reports of Mindfulness, Posttraumatic Growth, and Social\n                    Connectedness in Psilocybin-Assisted Group Therapy: An Interpretive\n                    Phenomenological Analysis","author":"G Agin-Liebes","year":"2021","journal-title":"J Humanist Psychol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding\n                    necessary","volume":"17","author":"A R Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and Psychedelic-Assisted Psychotherapy","volume":"177","author":"C M Reiff","year":"2020","journal-title":"Am J Psychiatry"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psychotherapy.20200055","article-title":"Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted\n                    Psychotherapy","volume":"74","author":"D Horton","year":"2021","journal-title":"Am J Psychother"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/09540261.2018.1486289","article-title":"Current perspectives on psychedelic therapy: use of serotonergic hallucinogens\n                    in clinical interventions","volume":"30","author":"A Garcia-Romeu","year":"2018","journal-title":"Int Rev Psychiatry Abingdon Engl"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jad.2021.09.041","article-title":"Dose effect of psilocybin on primary and secondary depression: a preliminary\n                    systematic review and meta-analysis","volume":"296","author":"N-X Li","year":"2022","journal-title":"J Affect Disord"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s15016-020-7549-z","article-title":"Therapie mit Psychedelika \u2013 die Rolle der Psychotherapie","volume":"31","author":"M Koslowski","year":"2020","journal-title":"NeuroTransmitter"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000467984","article-title":"LSD-assisted psychotherapy in patients with terminal cancer","volume":"8","author":"S Grof","year":"1973","journal-title":"Int Pharmacopsychiatry"},{"volume-title":"Human Encounter with Death","year":"1977","author":"S Grof","key":"ref101"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"M Johnson","year":"2008","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41398-021-01706-y","article-title":"Psilocybin therapy increases cognitive and neural flexibility in patients with\n                    major depressive disorder","volume":"11","author":"M K Doss","year":"2021","journal-title":"Transl Psychiatry"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive\n                    disorder: Prospective 12-month follow-up","volume":"36","author":"N Gukasyan","year":"2022","journal-title":"J Psychopharmacol (Oxf)"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/15733998113099990002","article-title":"Studying the effects of classic hallucinogens in the treatment of alcoholism:\n                    Rationale, methodology, and current research with psilocybin","volume":"6","author":"MP. Bogenschutz","year":"2013","journal-title":"Curr Drug Abuse Rev"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fphar.2018.00100","article-title":"Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted\n                    Psychotherapy for Alcohol Use Disorder","author":"M P Bogenschutz","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.drugalcdep.2012.11.010","article-title":"A survey of hallucinogenic mushroom use, factors related to usage, and\n                    perceptions of use among college students","volume":"130","author":"R M Hallock","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","article-title":"Efficacy, tolerability, and safety of serotonergic psychedelics for the\n                    management of mood, anxiety, and substance-use disorders: a systematic review of\n                    systematic reviews","volume":"11","author":"R G dos Santos","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.drugalcdep.2011.10.029","article-title":"Psilocybin dose-dependently causes delayed, transient headaches in healthy\n                    volunteers","volume":"123","author":"M W Johnson","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/swr\/svx011","article-title":"Within-Group Effect Size Benchmarks for Cognitive\u2013Behavioral Therapy in\n                    the Treatment of Adult Depression","volume":"41","author":"A Rubin","year":"2017","journal-title":"Soc Work Res"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jama.2009.1943","article-title":"Antidepressant drug effects and depression severity: a patient-level\n                    meta-analysis","volume":"303","author":"J C Fournier","year":"2010","journal-title":"JAMA"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of Psilocybin versus Escitalopram for Depression","volume":"384","author":"R Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled\n                    trials","volume":"14","author":"S D Muthukumaraswamy","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3109\/09540261.2010.496448","article-title":"Gender differences in antidepressant drug response","volume":"22","author":"R Keers","year":"2010","journal-title":"Int Rev Psychiatry"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1550-8579(06)80199-3","article-title":"Gender differences in depression and response to psychotropic medication","volume":"3","author":"JM. Gorman","year":"2006","journal-title":"Gend Med"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2046-5202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:10:23Z","timestamp":1730823023000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2046-5202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":111,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2024,6,14]]},"published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2046-5202","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"type":"print","value":"0720-4299"},{"type":"electronic","value":"1439-3522"}],"subject":[],"published":{"date-parts":[[2023,5,19]]}}}